-
Mashup Score: 2New Insights Into Secondary AML Treatment - 8 hour(s) ago
Eunice S. Wang, MD, discusses research behind optimal therapy for acute myeloid leukemia secondary to other malignancies, particularly in patients with prior myelodysplastic syndrome.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 1Influence of Nucleophosmin (NPM1) Genotypes on Outcome of Patients With AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration - 3 day(s) ago
PURPOSESeveral genomic subsets of NPM1 mutations with varying sequences (type A, B, D, etc) have been identified. Despite molecular heterogeneity, NPM1 mutations cumulatively portend a more favorable outcome, but biology and prognostic implications of …AML patients with NPM1 type D mutations show markedly poorer overall survival compared with other variants.
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Influence of Nucleophosmin (NPM1) Genotypes on Outcome of Patients With #AML: An AIEOP-BFM and COG-SWOG Intergroup Collaboration https://t.co/st6jVU2yea Authored by @MartinaPigazzi et al. #leusm https://t.co/MV8zb8iaK0
-
-
Mashup Score: 52
Click on the article title to read more.
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
The impact of post-remission G-CSF use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed #AML |American Journal of Hematology | Blood Research Journal | Wiley Online Library https://t.co/N6EeHvRkux #leusm https://t.co/fZqHEF04v5
-
-
Mashup Score: 48
Not all patients with acute myeloid leukaemia (AML) who achieve remission after induction therapy can proceed to haematopoietic stem cell transplantation (HSCT). For these patients, treatment options…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
Clinical perspectives on post-induction maintenance therapy in patients with #AML in remission who are ineligible for allogeneic haematopoietic stem cell transplantation #leusm |British Journal of Haematology | Wiley Online Library https://t.co/liQHk3P86Q https://t.co/jeu04pnEmc
-
-
Mashup Score: 71Unveiling the Role of New Molecules in Acute Myeloid Leukemia: Insights into Disease Pathogenesis and Therapeutic Potential - 18 day(s) ago
This review article explores the current landscape of acute myeloid leukemia treatment, including novel target molecules and recent advancements in cell therapy and immunotherapy focused on T cell activity. Advances in treatment have been promising in recent years, driven by the development of therapies targeting new molecular and genetic therapeutic targets. These findings allowed for the approval of several target therapies by the European and American drug agencies in the last 5 years. However, mortality remains very high, particularly in relapsed or refractory (R/R) patients. In recent years, the development of immunotherapy has expanded this field, leading to the introduction of new drugs and treatments.
Source: www.mdpi.comCategories: General Medicine News, Hem/OncsTweet-
Unveiling the Role of New Molecules in Acute Myeloid Leukemia: Insights into Disease Pathogenesis and Therapeutic Potential https://t.co/a7RobcVoHJ #AML #leusm https://t.co/JbrzpsERqi
-
-
Mashup Score: 0
A phase 2/3 study investigating uproleselan with standard 7+3 chemotherapy in newly diagnosed, older patients with acute myeloid leukemia did not achieve the primary end point of improved event-free survival.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Findings from a phase 2/3 study show that combining uproleselan with 7+3 chemotherapy did not significantly improve event-free survival vs chemotherapy in newly diagnosed #AML. #leusm https://t.co/k96wpWWVmC
-
-
Mashup Score: 0Iomab-B Leads to More Durable Responses vs alloHCT in AML Treatment - 3 month(s) ago
Findings from the phase 3 SIERRA study showed that Iomab-B was associated with a higher durable complete response rate vs allogeneic cell transplant in older patients with relapsed/refractory acute myeloid leukemia.
Source: www.targetedonc.comCategories: General Medicine News, Oncologists1Tweet-
Treatment with Iomab-B was linked to higher durable complete remission rates vs conventional care among older patients with relapsed/refractory #AML, according to findings from the phase 3 SIERRA study. #leusm | @MSKCancerCenter https://t.co/gm6YhtVmlq
-
-
Mashup Score: 2
PURPOSEOlder patients with relapsed or refractory AML (RR AML) have dismal prognoses without allogeneic hematopoietic cell transplantation (alloHCT). SIERRA compared a targeted pretransplant regimen involving the anti-CD45 radioconjugate 131I-apamistamab …See Miscellaneous Attachment
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Randomized Phase III SIERRA Trial of 131I-Apamistamab Before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory #AML: https://t.co/7SYgTcsR5Z @GiraltSergio #leusm
-
-
Mashup Score: 192Measurable residual disease monitoring in AML: Prospects for therapeutic decision‐making and new drug development - 3 month(s) ago
Measurable residual disease (MRD) is strongly associated with risk of relapse and long-term survival outcomes in patients with acute myeloid leukemia (AML). Apart from its clear prognostic impact, MR…
Source: onlinelibrary.wiley.comCategories: General Medicine News, Hem/OncsTweet-
MRD is highly prognostic in #AML and can inform SCT decisions or enrollment into MRD-directed clinical trials. MRD endpoints may also allow for accelerated drug approval in AML. New review by @NicholasShortMD and Richard Dillon in @AjHematology https://t.co/ZyUEAglDH7 #leusm https://t.co/WV3iMW5zln
-
-
Mashup Score: 0
PURPOSE Historically, patients with hematologic malignancies are referred to palliative care less often and later in the disease trajectory than those with solid tumors. Recent evidence demonstrates the benefit of early, integrated inpatient palliative care (PC) for patients with acute myeloid leukemia (AML) receiving chemotherapy at academic centers. The current study evaluated the feasibility of implementing standardized early palliative care services (PCS) during hospitalization for AML treatment in a community setting. METHODS Starting June 2018, automated consultations for PCS were incorporated into clinical pathways to encourage early, integrated services for patients receiving chemotherapy for AML with an expected hospital stay of 4-6 weeks. Expectations were established that consultations would be performed within 72 hours of request; patients would have two visits per week by a palliative care clinician and at least one visit by a member of the interdisciplinary team. To measu
Source: ascopubs.orgCategories: General Medicine News, Oncologists1Tweet-
Implementation of a Novel Pathway to Integrate Palliative and Oncology Care for Patients With Acute Myeloid Leukemia in a Community Hospital: https://t.co/7JceMtio2X @s_sivendran @kbnewport #AML #leusm
-
WATCH: Eunice S. Wang, MD, of @RoswellPark discusses research behind optimal therapy for #AML secondary to other malignancies, particularly in patients with prior myelodysplastic syndrome. #leusm https://t.co/A4b9DNiz1h